Supernus Indivior Merger Creates CNS Biopharma Leader
Supernus Indivior merger links Indivior's record Q2 and raised 2026 guidance to a $1.0B special dividend, focusing traders on deal financing and leverage.
KEY TAKEAWAYS
- All-stock Supernus Indivior merger includes a $1.0B special dividend funded partly by a $650M committed term loan.
- Indivior reported record Q2 revenue of $343M and raised FY 2026 SUBLOCADE guidance to $1.01B-$1.05B.
- Pro forma company targets about $2.2B revenue, $888M adjusted EBITDA and $125M annual cost synergies.
HIGH POTENTIAL TRADES SENT DIRECTLY TO YOUR INBOX
Add your email to receive our free daily newsletter. No spam, unsubscribe anytime.
Supernus Pharmaceuticals, Inc. and Indivior Pharmaceuticals, Inc. announced on Aug. 3, 2026 a tax-free, all-stock merger of equals following Indivior’s record second-quarter results and raised 2026 guidance. The companies said the deal supports scale and cash generation for the combined central nervous system (CNS) business.
Merger Terms, Financing, and Pro Forma Scale
The companies signed a definitive agreement unanimously approved by both boards to merge, forming a combined company named Supernus, Inc., which will list on the Nasdaq Global Market under the ticker SUPN. Each Supernus share will convert into 1.5401 Indivior common shares, a fixed exchange ratio. On a fully diluted basis, Indivior stockholders are expected to own about 56.5% of the combined company, with Supernus stockholders holding roughly 43.5%. The structure calls for Supernus to merge into a wholly owned Indivior subsidiary.
The deal includes a one-time special cash dividend of $1.0 billion to Indivior stockholders immediately before closing. This dividend will be funded by a committed $650 million senior secured term loan and $350 million from existing cash. Proceeds from the loan and available cash are conditions to closing.
The combined company will have pro forma trailing 12-month net revenue of about $2.2 billion as of June 30, 2026, and adjusted EBITDA of roughly $888 million, including targeted annual cost synergies of $125 million. Net debt at closing is expected near $878 million, implying net leverage below 1x adjusted EBITDA. The portfolio will include 11 marketed CNS medicines across neurology, psychiatry, and addiction, featuring SUBLOCADE and treatments for epilepsy, migraine, Parkinson’s disease, and ADHD. The companies said the merger “accelerates profitable growth and cash flow generation.”
Governance will include Jack Khattar, Supernus’s president and CEO, as president, CEO, and board member of the combined company. Tony Kingsley, an Indivior board member, will serve as board chair. The board will have eight directors evenly split between the two companies.
The companies disclosed reciprocal termination fees: Supernus would owe $101 million and Indivior $174 million in specified termination scenarios. The transaction remains subject to stockholder approvals, antitrust clearance under the Hart-Scott-Rodino Act, Nasdaq listing approval, and the effectiveness of a Form S-4 registration statement with the SEC. The parties target closing in the fourth quarter of 2026.
Indivior’s Strong Quarter Supports the Deal
Indivior reported total net revenue of $343 million for the quarter ended June 30, 2026, up 14% year-over-year. SUBLOCADE net revenue reached $253 million, a 21% increase and a record quarterly level. The company posted GAAP net income of $122 million, non-GAAP net income of $142 million, and adjusted EBITDA of $186 million, a 111% increase year-over-year.
Indivior repurchased 4,664,540 shares for about $175 million at an average price of $37.52. It raised full-year 2026 guidance to total net revenue of $1.295 billion to $1.365 billion and SUBLOCADE net revenue to $1.01 billion to $1.05 billion. At the midpoints, management said these ranges imply roughly 20% SUBLOCADE growth and about 68% adjusted EBITDA growth for 2026. Indivior reiterated its “Phase II – Accelerate” strategy and expects to close the merger on schedule.
Supernus also reported strong second-quarter results with total revenues of $219.1 million, up 32% year-over-year. Sales of four growth products totaled $175.7 million, a 52% increase. The quarter included $13.5 million in ONAPGO net sales and $35.4 million in collaboration revenue from ZURZUVAE. A non-cash $54.9 million APOKYN intangible asset impairment contributed to a GAAP operating loss. Supernus reported a GAAP loss per share of $1.01 and adjusted earnings per share of $0.53. The company raised its 2026 outlook following the quarter’s strength.
The companies emphasize the merger as a targeted, scale-building combination of complementary neurology, psychiatry, and addiction franchises, focusing on cash flow and capacity for business development and pipeline investment.
